Skip to Content
Merck
CN

Patients' perceptions of topical treatments of actinic keratosis.

The Journal of dermatological treatment (2012-12-12)
Solveig Esmann, Gregor B E Jemec
ABSTRACT

In recent years, a number of topical treatments suitable for field-directed therapy of actinic keratosis (AK) have been developed. Non-surgical treatment of AK however requires strict adherence by patients. Patients' views on the different possible topical treatments are therefore relevant to the choice of treatment. The aim of the study was to disclose the "silent perspectives" by focusing on user experiences and individual perspectives on topical treatment. Telephone interviews and face-to-face interviews were conducted with patients having had treatment with one or more of the following: imiquimod 5%, diclofenac sodium gel 3%, 5-fluorouracil (5-FU) cream 5% or photodynamic therapy. 24 patients with AK were interviewed. Experiences of pain, discharging ulcers and efficiency of the treatment were of major importance. There was a general focus on appearance, social contacts and leisure time, although this appeared to be of lesser importance. Patients' perception of treatment instructions identified a risk of misunderstandings. Patients are primarily concerned with therapeutic efficiency. Pain and ulcers are central indicators, but appearance, social contacts and leisure time can also be considered as additional indicators of satisfaction. A firm focus on patient instruction is suggested.

MATERIALS
Product Number
Brand
Product Description

Supelco
Diclofenac sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Imiquimod, ≥98% (HPLC), solid
Sigma-Aldrich
Diclofenac sodium salt
Sigma-Aldrich
5-Fluorouracil, ≥99% (HPLC), powder
Sigma-Aldrich
Fluorouracil, meets USP testing specifications
Supelco
5-Fluorouracil, analytical standard
Supelco
Diclofenac sodium salt, analytical standard
Diclofenac for system suitability, European Pharmacopoeia (EP) Reference Standard
Diclofenac potassium, European Pharmacopoeia (EP) Reference Standard
Fluorouracil, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
5-Fluorouracil, Vetec, reagent grade, ≥99%
Supelco
Fluorouracil, Pharmaceutical Secondary Standard; Certified Reference Material
Diclofenac sodium, European Pharmacopoeia (EP) Reference Standard
USP
Diclofenac sodium, United States Pharmacopeia (USP) Reference Standard